RxDoctor Payments DataLook up a doctor →

James Harvey, MD

Family Medicine · Fort Worth, TXNPI 1427076926

Payments from drug & device makers

$2,701,548in general payments, 2019–2025

Across 427 payments — averaging $6326.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2.3M
  • Boehringer Ingelheim$413K
  • Boehringer Ingelheim International GmbH$20K
  • Janssen Research & Development, LLC$15K
  • Novo Nordisk AS$1K
  • Amgen$215
  • plus $594 from 13 others
$2,054in research payments, 2019–2025

Across 6 payments — averaging $342.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$2K

What the payments were for

  • Food & beverage$76890%
  • Education$8410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,701,548 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,503
Medicare patients
73
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$34,735
OzempicSemaglutide22$21,901
Xtampza ErOxycodone Myristate14$16,201
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,757
XareltoRivaroxaban13$14,955
TrulicityDulaglutide12$13,804
Janumet XrSitagliptin Phos/Metformin Hcl13$5,889
SymbicortBudesonide/Formoterol Fumarate19$4,611
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,610
LivaloPitavastatin Calcium12$3,902
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$3,272
SynthroidLevothyroxine Sodium24$2,808
Advair DiskusFluticasone Propion/Salmeterol11$2,173
Metoprolol Succinate135$2,060
Duloxetine Hcl100$2,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$34,73533 claims
Novo NordiskOzempic$65$21,90122 claims
Johnson & JohnsonXarelto$62$14,95513 claims
Lilly USA, LLCTrulicity$37$13,80412 claims
AbbVieSynthroid$123$2,80824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →